83 related articles for article (PubMed ID: 9708515)
21. Lung tumor imaging by positron emission tomography using C-11 L-methionine.
Kubota K; Matsuzawa T; Ito M; Ito K; Fujiwara T; Abe Y; Yoshioka S; Fukuda H; Hatazawa J; Iwata R
J Nucl Med; 1985 Jan; 26(1):37-42. PubMed ID: 2981300
[TBL] [Abstract][Full Text] [Related]
22. Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study.
Lapela M; Leskinen-Kallio S; Varpula M; Grénman S; Salmi T; Alanen K; Någren K; Lehikoinen P; Ruotsalainen U; Teräs M
J Nucl Med; 1995 Dec; 36(12):2196-200. PubMed ID: 8523104
[TBL] [Abstract][Full Text] [Related]
23. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI.
Braams JW; Pruim J; Freling NJ; Nikkels PG; Roodenburg JL; Boering G; Vaalburg W; Vermey A
J Nucl Med; 1995 Feb; 36(2):211-6. PubMed ID: 7830116
[TBL] [Abstract][Full Text] [Related]
24. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum.
Nettelbladt OS; Sundin AE; Valind SO; Gustafsson GR; Lamberg K; Långström B; Björnsson EH
J Nucl Med; 1998 Apr; 39(4):640-7. PubMed ID: 9544671
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer.
Machtay M; Natwa M; Andrel J; Hyslop T; Anne PR; Lavarino J; Intenzo CM; Keane W
Head Neck; 2009 Feb; 31(2):195-201. PubMed ID: 19107945
[TBL] [Abstract][Full Text] [Related]
26. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine.
Reinhardt MJ; Kubota K; Yamada S; Iwata R; Yaegashi H
J Nucl Med; 1997 Feb; 38(2):280-7. PubMed ID: 9025756
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the accumulation of (11)C-methionine with standardized uptake value in the normal brain.
Uda T; Tsuyuguchi N; Terakawa Y; Takami T; Ohata K
J Nucl Med; 2010 Feb; 51(2):219-22. PubMed ID: 20080891
[TBL] [Abstract][Full Text] [Related]
28. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis.
Yamada Y; Uchida Y; Tatsumi K; Yamaguchi T; Kimura H; Kitahara H; Kuriyama T
J Nucl Med; 1998 Jul; 39(7):1160-6. PubMed ID: 9669387
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.
Nowak B; Di Martino E; Jänicke S; Cremerius U; Adam G; Zimny M; Reinartz P; Büll U
Nuklearmedizin; 1999; 38(8):312-8. PubMed ID: 10615664
[TBL] [Abstract][Full Text] [Related]
30. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET.
Rege SD; Chaiken L; Hoh CK; Choi Y; Lufkin R; Anzai Y; Juillard G; Maddahi J; Phelps ME; Hawkins RA
Radiology; 1993 Dec; 189(3):807-12. PubMed ID: 8234708
[TBL] [Abstract][Full Text] [Related]
31. Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.
Lindholm P; Minn H; Leskinen-Kallio S; Bergman J; Ruotsalainen U; Joensuu H
J Nucl Med; 1993 Jan; 34(1):1-6. PubMed ID: 8418248
[TBL] [Abstract][Full Text] [Related]
32. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
AAssar OS; Fischbein NJ; Caputo GR; Kaplan MJ; Price DC; Singer MI; Dillon WP; Hawkins RA
Radiology; 1999 Jan; 210(1):177-81. PubMed ID: 9885604
[TBL] [Abstract][Full Text] [Related]
33. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
34. FDG PET in head and neck cancer.
Keyes JW; Watson NE; Williams DW; Greven KM; McGuirt WF
AJR Am J Roentgenol; 1997 Dec; 169(6):1663-9. PubMed ID: 9393187
[TBL] [Abstract][Full Text] [Related]
35. Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET).
van Eijkeren ME; De Schryver A; Goethals P; Poupeye E; Schelstraete K; Lemahieu I; De Potter CR
Acta Oncol; 1992; 31(5):539-43. PubMed ID: 1419100
[TBL] [Abstract][Full Text] [Related]
36. [A useful method to evaluate 11C-methionine uptake using positron emission tomography: determination of the optimal scanning time for evaluation and a comparison between the tumor-to-muscle ratio and the distribution absorption ratio].
Sasaki M; Akashi Y; Ichiya Y; Kuwabara Y; Yoshida T; Fukumura T; Masuda K
Kaku Igaku; 1994 Dec; 31(12):1547-52. PubMed ID: 7861654
[TBL] [Abstract][Full Text] [Related]
37. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer.
Huovinen R; Leskinen-Kallio S; Någren K; Lehikoinen P; Ruotsalainen U; Teräs M
Br J Cancer; 1993 Apr; 67(4):787-91. PubMed ID: 8471437
[TBL] [Abstract][Full Text] [Related]
38. PET and [11C]methionine in assessment of response in non-Hodgkin lymphoma.
Leskinen-Kallio S; Minn H; Joensuu H
Lancet; 1990 Nov; 336(8724):1188. PubMed ID: 1978041
[No Abstract] [Full Text] [Related]
39. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.
Heuveling DA; de Bree R; Vugts DJ; Huisman MC; Giovannoni L; Hoekstra OS; Leemans CR; Neri D; van Dongen GA
J Nucl Med; 2013 Mar; 54(3):397-401. PubMed ID: 23334725
[TBL] [Abstract][Full Text] [Related]
40. A study on the prognostic evaluation of carbon ion radiotherapy for head and neck adenocarcinoma with C-11 methionine PET.
Hasebe M; Yoshikawa K; Ohashi S; Toubaru S; Kawaguchi K; Sato J; Mizoe J; Tsujii H
Mol Imaging Biol; 2010 Oct; 12(5):554-62. PubMed ID: 20369300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
